Ascelia Pharma AB (7ZA) AI Stock Analysis

Ascelia Pharma AB

(Frankfurt:7ZA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageVery low leverage limits interest and refinancing pressure while preserving flexibility to fund development or respond to setbacks. Although the company remains loss-making, its conservative debt profile reduces balance-sheet risk over the next several quarters.

Negative Factors

Pre-Revenue BusinessThe company has not yet established recurring product revenue, so its business model remains dependent on development success before commercial economics can emerge. The absence of revenue also means fixed development costs currently translate directly into continued operating losses.

Ascelia Pharma AB (7ZA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 7.07M
Dividend Yield: ―
Average Volume (3M): 13.00K
Price to Earnings (P/E): -1.2
Beta (1Y): 59.46
Revenue Growth: ―
EPS Growth: 56.56%
Country: Germany
Employees: 10
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Ascelia Pharma AB Business Overview & Revenue Model

Company Description

Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trial...

Ascelia Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:7ZA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ONCO	47Neutral	SEK 721.66M	-2.14	―	―	87.23%	35.27%
SE:BINV	43Neutral	SEK 357.32M	-0.73	-128.54%	―	-83.67%	-50.29%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%
SE:ONCOZ	38Underperform	SEK 85.84M	-1.62	-2775.09%	―	115.26%	-230.43%

* Healthcare Sector Average

Performance Comparison

DE:7ZA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:7ZA	Ascelia Pharma AB	0.04	-0.25	-84.98%
SE:BINV	BioInvent International AB	5.43	-28.47	-83.98%
SE:ONCO	Oncopeptides AB	1.67	-3.75	-69.16%
SE:ONCOZ	OncoZenge AB	3.11	-1.14	-26.75%
SE:IMMU	Immunicum AB	5.50	-1.89	-25.58%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ascelia Pharma AB AI Stock Analysis